



Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Member: **Cynthia Carlsson, M.D., M.S.**

Committee: **Peripheral and Central Nervous System Drugs Advisory Committee**

Meeting Date: **June 10, 2024**

I acknowledge that contingent upon public disclosure of the following financial interests related to the agenda item described below, I may be considered for participation in the advisory committee meeting.

On June 10, 2024, the Committee will discuss biologics license application (BLA) 761248, for donanemab solution for intravenous infusion, submitted by Eli Lilly and Company, for the treatment of early symptomatic Alzheimer’s disease.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
I. Personal/Immediate Family		
None		
II. Other Imputed Interests		
Contracts/grants	Employer’s research funded by Eisai (competing firm)	\$1,000,000 – \$2,000,000 to University of Wisconsin
Contracts/grants	Employer’s research funded by Cognition Therapeutics (competing firm)	\$1,000,000 – \$2,000,000 to University of Wisconsin, including 1% in salary support to Dr. Carlsson.
Contracts/grants	Employer’s research funded by Bristol Myers Squibb (competing firm)	Payment to University of Wisconsin is under negotiation. Likely to include 1 – 5% in salary support to Dr. Carlsson.

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

CYNTHIA
CARLSSON

 Digitally signed by CYNTHIA
CARLSSON
Date: 2024.05.24 10:13:12 -05'00'

Signature

Date